InflaRx N.V. (IFRX) Cash Flow Statement
Where IFRX’s cash came from and went, 2025
December 31, 2025 · euros- Cash from operations
- −€33.9M
- Capital expenditures
- €111,127 378.9% of revenue
- Free cash flow
- −€34.0M −116,026.4% margin
- Returned to shareholders
- —
- Change in cash
- −€179,657 cash at year-end €16.0M
Cash from operations
−€33.9M
Investments (net)
+€3.3M
Net borrowing (repayment)
−€357,583
Shares issued
+€22.9M
Other financing
+€9.5M
Currency & other
−€1.6M
Change in cash
−€179,657
Drawn to scale: where the cash came from and how it was used. Hover for values.
IFRX operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
IFRX cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −€5.0M2016 | −€33.9M2025 | — | |
| Capital expenditures | €53,0002016 | €111,1272025 | +8.6%/yr | |
| Free cash flow | −€5.0M2016 | −€34.0M2025 | — | |
| Free cash flow margin | −5,325.1%2017 | −116,026.4%2025 | −110,701.3 pts | |
| Stock-based compensation | €868,0002016 | €4.4M2025 | +19.9%/yr | |
| Dividends paid | €02016 | €02018 | — | |
| Share buybacks (net) | €02016 | €02019 | — | |
| Capex / revenue | 64.5%2017 | 378.9%2025 | +314.4 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
IFRX cash flow by activity
OperatingInvestingFinancingChange in cash
IFRX net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
IFRX cash flow statement in euros
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −€43.8M | −€46.1M | −€42.7M | −€29.5M | −€45.6M | −€34.0M | −€53.3M | −€29.8M | −€24.2M | −€8.9M |
| Depreciation & amortization | €419,483 | €485,114 | €567,780 | €596,597 | €669,434 | €712,713 | €663,166 | €173,630 | €70,910 | €33,000 |
| Stock-based compensation | €4.4M | €4.1M | €3.4M | €6.0M | €4.3M | €1.1M | €6.8M | €12.1M | €4.5M | €868,000 |
| Change in working capital | €4.7M | −€2.3M | €1.0M | −€9.8M | €1.5M | −€5.3M | −€2.3M | €1.8M | €2.6M | €1.2M |
| Other non-cash items | €383,587 | −€4.8M | −€131,291 | −€1.1M | −€846,548 | €972,084 | €4.9M | −€8.0M | €4.9M | €1.8M |
| Cash from operating activities | −€33.9M | −€48.6M | −€37.8M | −€33.7M | −€39.9M | −€36.5M | −€43.2M | −€23.7M | −€12.2M | −€5.0M |
| Investing activities | ||||||||||
| Capital expenditures | −€111,127 | −€46,871 | −€81,100 | −€162,391 | −€37,778 | −€94,189 | −€594,889 | −€806,000 | −€149,000 | −€53,000 |
| Investments (net) | €3.3M | €52.4M | −€18.7M | €19.4M | −€25.9M | €21.5M | €20.3M | −€99.5M | −€167,000 | −€53,000 |
| Acquisitions & other investing | −€132,169 | €46,871 | €1.1M | €162,391 | €0 | €0 | €594,889 | €806,000 | €149,000 | €53,000 |
| Cash from investing activities | €3.1M | €52.4M | −€17.7M | €19.4M | −€26.0M | €21.4M | €20.3M | −€99.5M | −€167,000 | −€53,000 |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | €0 | €0 | €0 |
| Share repurchases & issuance (net) | — | — | — | — | — | — | €1,680 | €53.4M | €118.0M | €30.9M |
| Net borrowing (repayment) | −€357,583 | −€388,114 | −€373,977 | −€364,430 | −€360,644 | −€366,156 | −€296,020 | −€296,020 | −€296,020 | −€296,020 |
| Shares issued | €22.9M | €1.1M | €58.8M | €2.3M | €65.1M | €9.8M | €0 | €53.4M | €0 | €0 |
| Other financing | €9.5M | −€323,729 | −€5.5M | −€47,735 | −€3.2M | −€232,895 | −€4 | −€56.9M | −€8.9M | €296,020 |
| Cash from financing activities | €32.0M | €386,446 | €53.0M | €1.9M | €61.6M | €9.2M | −€294,344 | €49.6M | €108.8M | €30.9M |
| Summary | ||||||||||
| Net change in cash | −€179,657 | €5.6M | −€3.5M | −€10.0M | €281,314 | −€7.2M | −€22.3M | −€67.9M | €94.2M | €25.8M |
| Cash at end of period | €16.0M | €18.4M | €12.8M | €16.3M | €26.2M | €26.0M | €33.1M | €55.4M | €123.3M | €29.1M |
| Free cash flow | −€34.0M | −€48.6M | −€37.9M | −€33.9M | −€40.0M | −€36.6M | −€43.8M | −€24.5M | −€12.3M | −€5.0M |
| Free cash flow margin | −116,026.4% | −29,316.5% | −60,064.5% | — | — | — | — | — | −5,325.1% | — |
| Capex / revenue | 378.9% | 28.3% | 128.5% | — | — | — | — | — | 64.5% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −€10.8M | −€5.7M | −€8.8M | −€12.3M | −€14.4M | −€8.3M | −€5.1M | −€17.4M | −€13.8M | −€9.7M | −€15.9M | −€7.5M |
| Depreciation & amortization | €92,081 | €87,182 | €90,889 | €99,793 | €115,000 | €113,801 | €110,737 | €111,445 | €138,983 | €123,949 | €135,532 | €138,920 |
| Stock-based compensation | €591,376 | €941,097 | −€3.6M | €595,879 | €1.1M | €2.5M | €339,900 | €652,094 | €1.2M | €1.9M | €452,998 | €722,094 |
| Change in working capital | €1.5M | −€1.5M | €6.8M | −€258,133 | €3.4M | −€5.3M | −€2.8M | €4.2M | €1.4M | −€5.1M | €937,119 | €4.4M |
| Other non-cash items | €6.1M | −€1.4M | €830,965 | €2.8M | €2.3M | −€3.0M | −€4.5M | €2.8M | −€1.0M | −€2.1M | €3.5M | −€3.0M |
| Cash from operating activities | −€2.6M | −€7.5M | −€4.7M | −€9.0M | −€7.6M | −€14.0M | −€11.9M | −€9.7M | −€12.1M | −€14.9M | −€10.9M | −€5.3M |
| Investing activities | ||||||||||||
| Capital expenditures | −€36,997 | −€9,620 | −€2,049 | −€87,972 | −€15,227 | −€10,446 | −€16,879 | −€1,682 | −€12,241 | −€16,069 | −€35,158 | −€21,269 |
| Investments (net) | €12.9M | €6.1M | €7.9M | €2.6M | −€24.9M | €17.7M | €2.0M | €17.5M | €6.0M | €26.9M | €2.8M | €7.4M |
| Acquisitions & other investing | €174,632 | €101,099 | €0 | €87,972 | €15,227 | €10,446 | €16,879 | €1,682 | €12,241 | €16,069 | €35,158 | €21,269 |
| Cash from investing activities | €13.0M | €6.2M | €7.9M | €2.6M | −€24.9M | €17.7M | €2.0M | €17.5M | €6.0M | €26.9M | €2.8M | €7.4M |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | −€76,840 | −€74,690 | −€72,726 | −€84,953 | −€99,807 | −€100,097 | −€97,969 | −€97,092 | — | — | — | −€94,284 |
| Shares issued | €127.4M | €0 | €6.8M | €0 | €0 | €16.1M | €1.1M | €0 | €0 | €0 | €0 | €0 |
| Other financing | −€6.1M | −€1,227 | −€192,533 | €0 | €232 | €11.0M | −€323,729 | €0 | −€107,347 | −€85,706 | −€94,901 | −€1 |
| Cash from financing activities | €121.3M | −€75,917 | €6.5M | −€84,953 | −€99,575 | €27.0M | €676,591 | −€97,092 | −€107,347 | −€85,706 | −€94,901 | −€94,285 |
| Summary | ||||||||||||
| Net change in cash | €131.4M | €8.4M | €9.6M | −€6.6M | −€34.3M | €28.9M | −€7.8M | €7.1M | −€6.0M | €12.3M | −€8.9M | €2.2M |
| Cash at end of period | €146.5M | €15.0M | €16.0M | €6.4M | €13.0M | €47.3M | €18.4M | €26.2M | €19.2M | €25.1M | €12.8M | €21.7M |
| Free cash flow | −€2.6M | −€7.5M | −€4.7M | −€9.1M | −€7.6M | −€14.0M | −€11.9M | −€9.7M | −€12.1M | −€14.9M | −€10.9M | −€5.3M |
| Free cash flow margin | — | — | — | −38,304.4% | −19,193.4% | — | — | −7,802.5% | −191,073.0% | −41,303.2% | −477,275.3% | −8,672.7% |
| Capex / revenue | — | — | — | 369.2% | 38.6% | — | — | 1.4% | 192.6% | 44.6% | 1,538.0% | 35.0% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported; data from EODHD.
IFRX cash generation
In fiscal 2025 (ended December 31, 2025), InflaRx generated -€33.9 million of cash from operations and spent €0.1 million on capital expenditures, leaving free cash flow of -€34.0 million, −116,026.4% of revenue. Cash and equivalents fell by €0.2 million over the year.
Related: IFRX income statement, IFRX balance sheet. See the IFRX stock overview for the latest quote and news.
IFRX cash flow FAQ
What is InflaRx's free cash flow?
InflaRx's free cash flow was -€34.0 million in fiscal 2025: -€33.9 million of operating cash flow minus €0.1 million of capital expenditures It was -€48.6 million a year earlier..
How much cash does InflaRx generate from operations?
InflaRx generated -€33.9 million of cash from operating activities in fiscal 2025.
How much does InflaRx spend on capital expenditures?
InflaRx spent €0.1 million on capital expenditures in fiscal 2025, 378.9% of revenue, compared with €0.0 million the year before.